Caplin Point Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹2614.20
Market cap
19,868 Cr
Stock P/E
29.9
P/B
5.47
Dividend yield
0.2%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 Cr | 805 Cr | 1,241 Cr | 1,694 Cr | 459 Cr | 942 Cr | 493 Cr | 502 Cr | 510 Cr | 534 Cr | 543 Cr | 600 Cr |
| Operating expenses (approx.) | 257 Cr | 509 Cr | 785 Cr | 1,075 Cr | 289 Cr | 586 Cr | 331 Cr | 309 Cr | 309 Cr | 315 Cr | 319 Cr | 368 Cr |
| EBITDA | 139 Cr | 296 Cr | 456 Cr | 619 Cr | 170 Cr | 356 Cr | 162 Cr | 194 Cr | 201 Cr | 220 Cr | 223 Cr | 233 Cr |
| OPM % | 35.1% | 36.8% | 36.7% | 36.5% | 37.1% | 37.8% | 32.9% | 38.6% | 39.4% | 41.1% | 41.2% | 38.8% |
| Other income | 12 Cr | 32 Cr | 50 Cr | 67 Cr | 19 Cr | 39 Cr | 31 Cr | 26 Cr | 23 Cr | 30 Cr | 34 Cr | 28 Cr |
| Interest | 0.28 Cr | 0.46 Cr | 0.63 Cr | 0.78 Cr | 0.05 Cr | 0.26 Cr | 0.18 Cr | 0.17 Cr | 0.18 Cr | 0.16 Cr | 0.18 Cr | 0.36 Cr |
| Depreciation | 11 Cr | 23 Cr | 37 Cr | 53 Cr | 16 Cr | 33 Cr | 16 Cr | 17 Cr | 16 Cr | 18 Cr | 19 Cr | 19 Cr |
| Profit before tax | 127 Cr | 273 Cr | 418 Cr | 564 Cr | 154 Cr | 323 Cr | 177 Cr | 177 Cr | 184 Cr | 201 Cr | 204 Cr | 213 Cr |
| Tax % | 17.9% | 19.3% | 18.7% | 18.3% | 19.1% | 20.8% | 21.0% | 17.8% | 18.3% | 20.3% | 18.7% | 19.0% |
| Net profit | 104 Cr | 220 Cr | 340 Cr | 461 Cr | 125 Cr | 256 Cr | 140 Cr | 145 Cr | 151 Cr | 160 Cr | 166 Cr | 173 Cr |
| EPS (₹) | ₹13.62 | ₹28.76 | ₹44.19 | ₹60.19 | ₹16.32 | ₹33.54 | ₹18.28 | ₹18.75 | ₹20.10 | ₹20.32 | ₹21.56 | ₹22.38 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 649 Cr | 1,061 Cr | 1,269 Cr | 1,467 Cr | 1,694 Cr | 1,937 Cr | 2,187 Cr | Sign in for TTM |
| Operating expenses (approx.) | 417 Cr | 709 Cr | 836 Cr | 1,026 Cr | 1,142 Cr | 1,194 Cr | 1,311 Cr | Sign in for TTM |
| EBITDA | 231 Cr | 352 Cr | 433 Cr | 441 Cr | 552 Cr | 743 Cr | 876 Cr | Sign in for TTM |
| OPM % | 35.7% | 33.2% | 34.1% | 30.1% | 32.6% | 38.4% | 40.1% | Sign in for TTM |
| Other income | 19 Cr | 24 Cr | 39 Cr | 56 Cr | 67 Cr | 96 Cr | 116 Cr | Sign in for TTM |
| Interest | 0.06 Cr | 2 Cr | 0.70 Cr | 0.78 Cr | 0.78 Cr | 0.61 Cr | 0.87 Cr | Sign in for TTM |
| Depreciation | 23 Cr | 37 Cr | 47 Cr | 45 Cr | 53 Cr | 66 Cr | 73 Cr | Sign in for TTM |
| Profit before tax | 227 Cr | 314 Cr | 386 Cr | 451 Cr | 564 Cr | 677 Cr | 803 Cr | Sign in for TTM |
| Tax % | 22.2% | 19.8% | 20.1% | 16.5% | 18.3% | 20.0% | 19.1% | Sign in for TTM |
| Net profit | 177 Cr | 251 Cr | 308 Cr | 377 Cr | 461 Cr | 541 Cr | 650 Cr | Sign in for TTM |
| EPS (₹) | ₹23.35 | ₹32.03 | ₹39.61 | ₹49.62 | ₹60.19 | ₹70.57 | ₹84.36 | Sign in for TTM |
| Dividend payout % | — | — | 7.4% | 8.0% | 7.4% | 7.0% | 7.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr |
| Reserves | 618 Cr | 1,171 Cr | 0.0000 Cr | 1,892 Cr | 2,332 Cr | 2,871 Cr | 3,571 Cr |
| Borrowings | 0.29 Cr | 0.01 Cr | — | 3 Cr | 1 Cr | 0.55 Cr | 0.57 Cr |
| Other liabilities | 109 Cr | 102 Cr | 124 Cr | 281 Cr | 349 Cr | 322 Cr | 414 Cr |
| Total liabilities | 743 Cr | 861 Cr | 1,054 Cr | 2,191 Cr | 2,697 Cr | 3,209 Cr | 4,045 Cr |
| Fixed assets (net) | 225 Cr | 178 Cr | 158 Cr | 267 Cr | 439 Cr | 530 Cr | 547 Cr |
| CWIP | 10 Cr | 1 Cr | 2 Cr | 220 Cr | 117 Cr | 139 Cr | 209 Cr |
| Investments | 70 Cr | 11 Cr | 265 Cr | 230 Cr | 376 Cr | 590 Cr | 859 Cr |
| Other assets | 567 Cr | 558 Cr | 736 Cr | 1,554 Cr | 1,892 Cr | 2,134 Cr | 2,586 Cr |
| Total assets | 743 Cr | 861 Cr | 1,054 Cr | 2,191 Cr | 2,697 Cr | 3,209 Cr | 4,045 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | 337 Cr | 272 Cr | 311 Cr | 432 Cr | 523 Cr |
| Cash from investing | — | — | -271 Cr | -218 Cr | -313 Cr | -335 Cr | -582 Cr |
| Cash from financing | — | — | -41 Cr | -28 Cr | -38 Cr | -38 Cr | -46 Cr |
| Net cash flow | — | — | 25 Cr | 26 Cr | -40 Cr | 59 Cr | -106 Cr |
| Free cash flow (OCF − Capex) | — | — | 246 Cr | 78 Cr | 165 Cr | 241 Cr | 275 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | 32.8% | 26.6% | 2549.6% | 20.7% | 21.2% | 23.5% | 22.1% |
| ROE % | 27.9% | 20.4% | 0.0% | 19.7% | 19.5% | 19.5% | 17.7% |
| Debtor days | 90 | 74 | 37 | 98 | 117 | — | — |
| Inventory days | 143 | 80 | 100 | 470 | 553 | 492 | 437 |
| Days payable | 231 | 227 | 169 | 268 | 319 | — | — |
| Cash conversion cycle | 2 | -72 | -32 | 300 | 351 | 492 | 437 |
| Debt / equity | 0.0005 | 0.0000 | — | 0.0018 | 0.0005 | 0.0002 | 0.0002 |
| Current ratio | 5.73 | 6.89 | 6.13 | 5.80 | 5.72 | 6.97 | 6.70 |
| Net debt / EBITDA | -0.21 | 0.00 | 0.00 | -0.39 | -0.25 | -0.27 | -0.11 |
Compare with peers
Loading peers…